BR0210224A - Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem - Google Patents

Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem

Info

Publication number
BR0210224A
BR0210224A BR0210224-2A BR0210224A BR0210224A BR 0210224 A BR0210224 A BR 0210224A BR 0210224 A BR0210224 A BR 0210224A BR 0210224 A BR0210224 A BR 0210224A
Authority
BR
Brazil
Prior art keywords
presented
dosage form
preparing
capsule formulation
dosage forms
Prior art date
Application number
BR0210224-2A
Other languages
English (en)
Inventor
Timothy James Grattan
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR0210224A publication Critical patent/BR0210224A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Abstract

"FORMAS DE DOSAGEM NãO EFERVESCENTE PROJETADA PARA SER ENGOLIDA DIRETAMENTE E APRESENTADA COMO UMA FORMULAçãO EM COMPRIMIDO OU CáPSULA DEGLUTìVEL, E, PROCESSO PARA PREPARAçãO DE UMA FORMA DE DOSAGEM". é descrita uma forma de dosagem como uma formulação em comprimido ou cápsula deglutível contendo paracetamol, baixos níveis de bicarbonato de sódio ou bicarbonato de potássio ou suas misturas e pelo menos um excipiente farmaceuticamente aceitável.
BR0210224-2A 2001-06-08 2002-06-03 Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem BR0210224A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114069.8A GB0114069D0 (en) 2001-06-08 2001-06-08 Composition
PCT/EP2002/006046 WO2002100391A1 (en) 2001-06-08 2002-06-03 Swallow tablet comprising paracetamol

Publications (1)

Publication Number Publication Date
BR0210224A true BR0210224A (pt) 2004-04-13

Family

ID=9916252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210224-2A BR0210224A (pt) 2001-06-08 2002-06-03 Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem

Country Status (25)

Country Link
US (1) US7993673B2 (pt)
EP (1) EP1392271B1 (pt)
JP (1) JP2004533461A (pt)
KR (1) KR100846945B1 (pt)
CN (1) CN1538837A (pt)
AR (1) AR036085A1 (pt)
AT (1) ATE389392T1 (pt)
AU (1) AU2002317772B2 (pt)
BR (1) BR0210224A (pt)
CA (1) CA2449520C (pt)
CO (1) CO5540295A2 (pt)
CZ (1) CZ301449B6 (pt)
DE (1) DE60225686T2 (pt)
DK (1) DK1392271T3 (pt)
ES (1) ES2300452T3 (pt)
GB (1) GB0114069D0 (pt)
HK (1) HK1062896A1 (pt)
HU (1) HUP0400127A2 (pt)
MX (1) MXPA03011317A (pt)
MY (1) MY136059A (pt)
NZ (1) NZ529974A (pt)
PL (1) PL367985A1 (pt)
TW (1) TWI326212B (pt)
WO (1) WO2002100391A1 (pt)
ZA (1) ZA200309172B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566384C (en) * 2004-05-28 2010-08-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
CA2566331C (en) * 2004-05-28 2011-03-15 Imaginot Pty Ltd. Oral delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
CN100356918C (zh) * 2004-09-30 2007-12-26 吴筑华 一种治疗肠炎的鞣酸苦参总碱肠溶速释制剂
EP1954298A4 (en) 2005-11-28 2012-10-31 Imaginot Pty Ltd DISPENSING SYSTEM FOR ORAL THERAPEUTIC CONNECTION
GB0607085D0 (en) 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
DE102007041588A1 (de) * 2007-09-01 2009-03-05 Lts Lohmann Therapie-Systeme Ag Arzneimittel mit Hefe
GB0813929D0 (en) * 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
BR112013028668A2 (pt) * 2011-05-06 2017-01-24 Glaxosmithkline Llc formulações de paracetamol de liberação sustentada
WO2014203140A1 (en) * 2013-06-22 2014-12-24 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation
CN108451916B (zh) * 2018-06-19 2020-08-14 重庆国泰康宁制药有限责任公司 一种对乙酰氨基酚药物组合物制剂及其制备方法
WO2020106735A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CN115998698B (zh) * 2023-02-07 2024-03-15 福州海王福药制药有限公司 一种碳酸氢钠片的制备工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3390049A (en) * 1964-12-23 1968-06-25 Smith Kline French Lab Pharmaceutical tablets coated with wax-free ammonia solubilized water soluble shellac
GB1583602A (en) 1977-05-26 1981-01-28 Sterwin Ag N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives
CA1182049A (en) * 1981-07-13 1985-02-05 Francis J. Sterbenz Apap antacid composition
US4915953A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering acetaminophen or phenylpropanolamine
US5073377A (en) 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
CA2021548A1 (en) * 1989-09-01 1991-03-02 Ronald Nash Duvall Effervescent cold or sinus allergy medicine composition having reduced sodium content
US5262179A (en) * 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
JP3412694B2 (ja) 1989-10-02 2003-06-03 シーマ・ラブス、インコーポレイテッド 発泡性投与剤
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
US5750145A (en) * 1995-07-28 1998-05-12 Bristol-Myers Squibb Company Stable gelatin coated aspirin tablets
US5807580A (en) 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
GB9704524D0 (en) 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
WO1999004758A1 (en) * 1997-07-25 1999-02-04 Elan Corporation Plc A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
DE19931708A1 (de) 1999-07-08 2001-01-18 Bayer Ag Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
US6277409B1 (en) * 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
ES2174734B1 (es) 2000-11-03 2003-10-01 Belmac S A Lab Nueva formulacion galenica de paracetamol dispersable y soluble, procedimiento para su preparacion y aplicaciones.

Also Published As

Publication number Publication date
CA2449520C (en) 2011-12-06
MY136059A (en) 2008-08-29
CZ301449B6 (cs) 2010-03-03
CZ20033340A3 (en) 2004-05-12
PL367985A1 (en) 2005-03-21
AU2002317772B2 (en) 2006-04-06
KR20040007665A (ko) 2004-01-24
WO2002100391A1 (en) 2002-12-19
CA2449520A1 (en) 2002-12-19
TWI326212B (en) 2010-06-21
MXPA03011317A (es) 2004-03-19
EP1392271B1 (en) 2008-03-19
CN1538837A (zh) 2004-10-20
NZ529974A (en) 2006-02-24
US20040170681A1 (en) 2004-09-02
ATE389392T1 (de) 2008-04-15
CO5540295A2 (es) 2005-07-29
DK1392271T3 (da) 2008-06-30
KR100846945B1 (ko) 2008-07-17
DE60225686T2 (de) 2009-04-16
ZA200309172B (en) 2004-11-25
HK1062896A1 (en) 2004-12-03
US7993673B2 (en) 2011-08-09
EP1392271A1 (en) 2004-03-03
JP2004533461A (ja) 2004-11-04
HUP0400127A2 (hu) 2004-07-28
DE60225686D1 (de) 2008-04-30
AR036085A1 (es) 2004-08-11
ES2300452T3 (es) 2008-06-16
GB0114069D0 (en) 2001-08-01

Similar Documents

Publication Publication Date Title
BR0210224A (pt) Formas de dosagem projetada para ser engolida diretamente e apresentada como uma formulação em comprimido ou cápsula deglutìvel, e, processo para preparação de uma forma de dosagem
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
HUP0101246A2 (hu) Meloxicam új galenusi formulációi orális alkalmazásra és eljárás az előállításukra
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
PE20030823A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
CO5190688A1 (es) Formas farmaceuticas de administracion oral al menos parcialmente retardadas cuya sustancia activa tramadol se encuentra al menos parcialmente en forma de compuesto formado in situ con una hidrosolubilidad 100 mg/ml, y procedimientos para su preparac
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
BR0107564A (pt) Composição de gliburida
TW200634001A (en) Novel compounds
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
HUP0300709A2 (hu) Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény
SE0102440D0 (sv) New compound
DK0527081T3 (da) Hidtil ukendte substituerede 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-oner, deres fremstilling og terapeutiske anvendelse
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
CO5640085A2 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
SE0000303D0 (sv) Novel compounds
KR960700701A (ko) 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof)
EA200501621A1 (ru) Антигриппозное средство

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/165, 9/20, 9/28; A61P 29/02

Ipc: A61K 31/165 (2011.01), A61K 9/20 (2011.01), A61K 9

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.